Drugs / MULNITORSEN
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03985072 | Apr 2019 → Feb 2022 | cervical carcinoma, colorectal carcinoma, exocrine pancreatic carcinoma, gallbladder cancer +2 | Andes Biotechnologies | Completed | No outcome recorded |
| Phase 1 | NCT02508441 | Dec 2015 → Nov 2017 | — | Andes Biotechnologies | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MULNITORSEN | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095135 ↗ |
| Known as | Andes-1537 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03985072 ↗ |
| Route | Subcutaneous | “Andes-1537 subcutaneous injection” NCT02508441 ↗ |